Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
RydaptⓇ - Multi-targeted kinase inhibitor
Company overview
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
> Oncology
Other
Global Health
Abbreviations
References
NCT03591510 (CPKC412A2218)
Acute myeloid leukemia, pediatrics
Indication
Phase
Phase 2
Patients
20
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Occurrence of dose limiting toxicities
Safety and Tolerability
Chemotherapy followed by Midostaurin
Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia
(AML)
Readout
Milestone(s)
2026
Publication
TBD
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
75View entire presentation